NCI-2021-02479

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies

This Phase I/II research study is testing a new cancer drug called BT8009 in people with advanced cancers that have a protein called Nectin-4 on their tumor cells. This protein is common in certain cancers like bladder, breast, and lung cancers. BT8009 is designed to deliver a toxin directly to cancer cells, aiming to kill them while causing fewer side effects than traditional chemotherapy. The first part of the study focuses on finding a safe dose and understanding how the drug behaves in the body, while the second part looks at how well it works to shrink tumors or slow their growth. The goal is to see if BT8009 could become a new treatment option for people whose cancers haven't responded to other therapies.

Phase I/II: A study that assesses the safety, effectiveness, and how well the treatment works 

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04561362

Clinical Trial Site: Sinai

To see all available clinical trials click here.